Although I am glad they finally moved on this one and got...

Although I am glad they finally moved on this one and got something going, not so sure about the target company (maybe the board felt pressured to move quickly given the new -and pending- ASX rules relating to RTO's?). Smells a bit like the key players are looking after themselves and get set quickly before (all) the rule changes come into effect. Not much potential for short term sp increases with this one given the BCAL Dx is merely in proof of concept stage. Larger clinical studies take time and before you get to approved products, if ever, years will go by. This is going to be a very, very long road imo.